MCID: DPH001
MIFTS: 63

Diphtheria

Categories: Rare diseases, Infectious diseases

Aliases & Classifications for Diphtheria

MalaCards integrated aliases for Diphtheria:

Name: Diphtheria 12 72 49 55 51 40 3 41 14 69
Corynebacterium Infections 41 69
Diphtheria, Susceptibility to 13
Corynebacterium Infection 12

Characteristics:

Orphanet epidemiological data:

55
diphtheria
Prevalence: <1/1000000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 55  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:11405
SNOMED-CT 64 397434007
Orphanet 55 ORPHA1679
MESH via Orphanet 42 D004165
UMLS via Orphanet 70 C0012546
ICD10 via Orphanet 33 A36.0 A36.1 A36.2 more
ICD10 32 A36 A36.9

Summaries for Diphtheria

MedlinePlus : 40 Diphtheria is a serious bacterial infection. You can catch it from a person who has the infection and coughs or sneezes. You can also get infected by coming in contact with an object, such as a toy, that has bacteria on it. Diphtheria usually affects the nose and throat. Symptoms include Sore throat Swollen glands in the neck Fever Weakness Your doctor will diagnose it based on your signs and symptoms and a lab test. Getting treatment for diphtheria quickly is important. If your doctor suspects that you have it, you'll start treatment before the lab tests come back. Treatment is with antibiotics. The diphtheria, pertussis, and tetanus vaccine can prevent diphtheria, but its protection does not last forever. Children need another dose, or booster, at about age 12. Then, as adults, they should get a booster every 10 years. Diphtheria is very rare in the United States because of the vaccine. Centers for Disease Control and Prevention

MalaCards based summary : Diphtheria, also known as corynebacterium infections, is related to tetanus and mucositis, and has symptoms including equilibration disorder, vertigo/dizziness and sore throat. An important gene associated with Diphtheria is HBEGF (Heparin Binding EGF Like Growth Factor), and among its related pathways/superpathways are Metabolism of proteins and Developmental Biology. The drugs Natalizumab and Edetic Acid have been mentioned in the context of this disorder. Affiliated tissues include heart, kidney and skin, and related phenotypes are Increased viability with SS1P at EC90 and growth/size/body region

CDC : 3 Diphtheria is an infection caused by the bacterium Corynebacterium diphtheriae. Diphtheria causes a thick covering in the back of the throat. It can lead to difficulty breathing, heart failure, paralysis, and even death. Vaccines are recommended for infants, children, teens and adults to prevent diphtheria.

Disease Ontology : 12 A primary bacterial infectious disease that is characterized by sore throat, low fever, and an adherent membrane (a pseudomembrane) on the tonsils, pharynx, and/or nasal cavity. A milder form of diphtheria can be restricted to the skin. It is caused by Corynebacterium diphtheriae, an aerobic Gram-positive bacterium. Diphtheria toxin spreads through the bloodstream and can lead to potentially life-threatening complications that affect other organs of the body, such as the heart and kidneys.

Wikipedia : 72 Diphtheria is an infection caused by the bacterium Corynebacterium diphtheriae. Signs and symptoms may... more...

Related Diseases for Diphtheria

Diseases related to Diphtheria via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 178)
# Related Disease Score Top Affiliating Genes
1 tetanus 31.0 IL13 IL2 IL2RA
2 mucositis 29.6 CSF2 EGF IL2
3 leukemia, acute myeloid 29.4 CSF2 IL2 IL3 PARP1
4 malaria 27.8 CSF2 IL13 IL2 IL2RB PLAUR
5 cutaneous diphtheria 12.5
6 granulomatous lobular mastitis 10.9
7 pseudomembranous conjunctivitis 10.9
8 diphtheritic peritonitis 10.9
9 specific antibody deficiency 10.9
10 pertussis 10.8
11 influenza 10.5
12 haemophilus influenzae 10.4
13 hepatitis 10.4
14 aging 10.4
15 hepatitis b 10.4
16 primary bacterial infectious disease 10.3 EEF2 HBEGF IL2
17 poliomyelitis 10.3
18 scarlet fever 10.3
19 virus associated hemophagocytic syndrome 10.3 IL2 IL2RB
20 measles 10.2
21 leukemia 10.2
22 large granular lymphocyte leukemia 10.2 CSF2 IL2RA
23 rheumatoid factor-negative juvenile idiopathic arthritis 10.2 IL2RA IL2RB
24 capillary disease 10.1 CSF2 IL2
25 myeloid leukemia 10.0
26 b-cell expansion with nfkb and t-cell anergy 10.0 IL2 IL2RA IL2RB
27 seborrheic infantile dermatitis 10.0 CSF2 IL3
28 pulmonary sarcoidosis 10.0 CSF2 IL2 IL2RA
29 visceral leishmaniasis 10.0 EEF2 IL13 IL2
30 polykaryocytosis inducer 9.9
31 mumps 9.9
32 rubella 9.9
33 acquired immunodeficiency syndrome 9.9 CSF2 IL2 IL2RA
34 endocarditis 9.9
35 myocarditis 9.9
36 atopic keratoconjunctivitis 9.9 IL2 IL3
37 bladder cancer 9.9
38 glioblastoma 9.9
39 immune deficiency disease 9.9 IL2 IL2RA IL2RB
40 hairy cell leukemia 9.9 IL2 IL2RA IL3
41 mastitis 9.8
42 granulomatous mastitis 9.8
43 pancreatic cancer 9.8
44 multiple mitochondrial dysfunctions syndrome 5 9.8
45 hepatitis a 9.8
46 melanoma 9.8
47 pancreatitis 9.8
48 neuronitis 9.8
49 blood group, i system 9.8
50 ovarian cancer 9.8

Comorbidity relations with Diphtheria via Phenotypic Disease Network (PDN):


Acute Cystitis

Graphical network of the top 20 diseases related to Diphtheria:



Diseases related to Diphtheria

Symptoms & Phenotypes for Diphtheria

UMLS symptoms related to Diphtheria:


equilibration disorder, vertigo/dizziness, sore throat, tinnitus, snoring, pruritus, fever, coughing

GenomeRNAi Phenotypes related to Diphtheria according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased viability with SS1P at EC90 GR00376-A-1 9.02 DNAJC24 DPH1 DPH2 DPH3 FURIN

MGI Mouse Phenotypes related to Diphtheria:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.27 PLAUR TXNRD1 IL2RB PARP1 IL2RA EEF2
2 embryo MP:0005380 10.06 PARP1 TXNRD1 IL2RB DPH3 EEF2 FURIN
3 hematopoietic system MP:0005397 10.06 PARP1 PLAUR IL2RA IL2RB CD9 FURIN
4 immune system MP:0005387 10 PARP1 PLAUR IL2RA IL2RB IL2 EGF
5 mortality/aging MP:0010768 9.8 PARP1 TXNRD1 IL2RB DPH3 IL2RA EEF2
6 integument MP:0010771 9.76 PARP1 IL2RB EGF FURIN CSF2 HBEGF
7 respiratory system MP:0005388 9.23 PLAUR IL2RA CD9 CSF2 HBEGF IL13

Drugs & Therapeutics for Diphtheria

Drugs for Diphtheria (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 178)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Natalizumab Approved, Investigational Phase 4 189261-10-7
2
Edetic Acid Approved, Vet_approved Phase 4,Phase 3,Phase 2 60-00-4, 62-33-9 6049
3
Iron Approved Phase 4,Phase 3,Phase 2 7439-89-6 23925
4
Adalimumab Approved Phase 4 331731-18-1 16219006
5
Etanercept Approved, Investigational Phase 4 185243-69-0
6
Daclizumab Approved, Investigational Phase 4 152923-56-3
7
Acetaminophen Approved Phase 4,Phase 3 103-90-2 1983
8
Ibuprofen Approved Phase 4 15687-27-1 3672
9
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
10
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
11
Lopinavir Approved Phase 4 192725-17-0 92727
12
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
13
Lactitol Investigational Phase 4,Phase 3,Phase 2 585-86-4 3871
14
BCG vaccine Investigational Phase 4,Phase 2
15 Vaccines Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
16 Heptavalent Pneumococcal Conjugate Vaccine Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
17 Protective Agents Phase 4,Phase 3,Phase 2
18 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
19 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
20 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1
21 Aluminum phosphate Phase 4,Phase 3,Phase 1,Phase 2
22 Antacids Phase 4,Phase 3,Phase 2,Phase 1
23 Anti-Ulcer Agents Phase 4,Phase 3,Phase 2,Phase 1
24 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
25 Antidotes Phase 4,Phase 3,Phase 2
26 Antitoxins Phase 4,Phase 3
27 Diphtheria Antitoxin Phase 4,Phase 3
28 Tetanus Antitoxin Phase 4,Phase 3
29 Keyhole-limpet hemocyanin Phase 4,Phase 1
30 Anticoagulants Phase 4,Phase 3,Phase 2
31 Calcium, Dietary Phase 4,Phase 3,Phase 2
32 Chelating Agents Phase 4,Phase 3,Phase 2
33 Iron Chelating Agents Phase 4,Phase 3,Phase 2
34 Pentetic Acid Phase 4,Phase 3,Phase 2
35 Fibrinolytic Agents Phase 4,Phase 3,Phase 2
36 PENTA Phase 4,Phase 3,Phase 2
37 Antirheumatic Agents Phase 4,Phase 2
38 Interleukin 1 Receptor Antagonist Protein Phase 4
39 MF59 oil emulsion Phase 4,Phase 2
40 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
41 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1
42 Anti-Inflammatory Agents Phase 4,Phase 3
43 Anti-Inflammatory Agents, Non-Steroidal Phase 4
44 Immunosuppressive Agents Phase 4,Phase 2
45 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
46 Antibodies, Monoclonal Phase 4,Phase 3,Phase 2
47 Antipyretics Phase 4,Phase 3
48 Cyclooxygenase Inhibitors Phase 4
49 Anti-HIV Agents Phase 4,Phase 1
50 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 534)

# Name Status NCT ID Phase Drugs
1 An Immunogenicity and Safety Study of Tetanus, Diphtheria and Acellular Pertussis Vaccine Booster Unknown status NCT00870350 Phase 4
2 Vaccination Against Pertussis, Tetanus and Diphtheria in Patients Suffering From Rheumatoid Arthritis Unknown status NCT01301703 Phase 4
3 The Safety and Immunogenicity of Acellular Pertussis Vaccine in Bone Marrow Transplant Recipients Unknown status NCT00336115 Phase 4
4 Safety, Long Term Immunogenicity and Lot Consistency Study of Liquid Pentavalent Combination Vaccine Unknown status NCT00877357 Phase 4
5 Diphtheria, Tetanus, Poliomyelitis -Pertussis-Hib Immunisation in Preterm-born Neonates Unknown status NCT02179996 Phase 4
6 Canadian Manufactured Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine Compared With U.S. Manufactured Td Completed NCT00601835 Phase 4
7 Immunogenicity and Safety Study of a Booster Dose (5th) of Diphteria-Tetanus-Pertussis-Polio Vaccine Completed NCT00514059 Phase 4 Boostrix polio
8 Immunogenicity and Safety of Concomitant Administration of RotaTeq™ (V260) and the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Healthy Japanese Infants (V260-060) Completed NCT01926015 Phase 4
9 Immune Responses in Adults to Revaccination With ADACEL® 10 Years After a Previous Dose Completed NCT00712959 Phase 4
10 Descriptive, Open-label, Multicenter Study of the Safety of Redosing With ADACEL® Vaccine Completed NCT00347958 Phase 4
11 Phase IV Interchangeability Study of a Liquid Pentavalent Combination Vaccine Completed NCT00674908 Phase 4
12 Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age Completed NCT01659996 Phase 4
13 A Trial to Evaluate the Safety and Immunogenicity of ADACEL® Vaccine in Persons 65 Years of Age and Older Completed NCT00457249 Phase 4
14 Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose Completed NCT01439165 Phase 4
15 US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Disease Completed NCT00282295 Phase 4
16 Study of Adacel® Vaccine Administered to Persons 10 Years of Age Completed NCT01311557 Phase 4
17 Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents Completed NCT01629589 Phase 4
18 Post-licensure, Modified Double-blind, Multi-center Study Evaluating Safety and Immunogenicity of ADACEL® and BOOSTRIX® Completed NCT00319553 Phase 4
19 Evaluation of Immunogenicity and Safety of the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus (DPT-IPV) Vaccine Squarekids™ Co-administered With GSK Biologicals' Human Rotavirus (HRV) Vaccine Rotarix™ (GSK444563) in Healthy Infants Completed NCT02907216 Phase 4
20 Maternal Flu Vaccine Trial in Bamako, Mali Completed NCT01430689 Phase 4
21 Post-marketing Evaluation of Reactions Following Receipt of Recommended Adolescent Pertussis Vaccine Completed NCT00304265 Phase 4
22 Post Marketing Surveillance for ADACEL™ in South Korea Completed NCT01137435 Phase 4
23 A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents Completed NCT01424644 Phase 4
24 Antibody Persistence to REVAXIS or DT Polio and Immune Response to TETRAVAC-ACELLULAIRE Completed NCT01546909 Phase 4
25 Tdap Vaccine in Post-Partum Women Completed NCT01711645 Phase 4
26 Regulatory Post-Marketing Surveillance Study for TETRAXIM™ Completed NCT01437423 Phase 4
27 A Trial Evaluating a 7-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants. Completed NCT01250756 Phase 4
28 Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap Vaccine Completed NCT00777257 Phase 4
29 Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™ Completed NCT00802867 Phase 4
30 Randomized Study of Not Giving Diphteria-tetanus-pertussis Vaccination With or After Measles Vaccination Completed NCT00244673 Phase 4
31 Safety and Immunogenicity Study of a Liquid Pentavalent Combination Vaccine Completed NCT00617812 Phase 4
32 Assessment of the Immunogenicity and Safety of PENTAXIM™ in Philippines Completed NCT00254917 Phase 4
33 Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination. Completed NCT00610168 Phase 4
34 Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult Subjects Completed NCT02591290 Phase 4
35 Study to Assess if Quinvaxem Can be Interchanged With Other Pentavalent Vaccines During Standard Childhood Vaccination Completed NCT01357720 Phase 4
36 Concomitant Use of Hepatitis A Vaccine, Inactivated With Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) and Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Given to Healthy Children 15 Months of Age (V251-068) Completed NCT00289913 Phase 4
37 Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines Completed NCT01270503 Phase 4
38 Immunogenicity and Safety of Booster Dose of BoostrixTM Polio Vaccine in Previously Boosted Adults Completed NCT01323959 Phase 4
39 Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose Completed NCT01823536 Phase 4
40 Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination Completed NCT00548171 Phase 4
41 Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand Completed NCT00255021 Phase 4
42 Evaluation of Boostrix™10 Years After Previous Booster Vaccination Completed NCT01147900 Phase 4
43 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Pregnant Women Completed NCT02377349 Phase 4 Saline placebo
44 Tropical Influenza Control Strategies for the Elderly Completed NCT02655874 Phase 4
45 Immunogenicity and Safety of TETRAXIM™ Given as a Booster Dose at 4 to 6 Years of Age Completed NCT01031303 Phase 4
46 The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis Completed NCT00536120 Phase 4
47 Immunogenicity and Reactogenicity Study of BoostrixTM (dTpa) and Boostrix-IPV (dTpa-IPV) Completed NCT01294605 Phase 4
48 Descriptive, Post-marketing, Surveillance Safety Study of Menactra Vaccine Completed NCT00254995 Phase 4
49 Immunology of Non-specific Effects of Vaccine Completed NCT00168545 Phase 4
50 Immunogenicity and Safety of BoostrixTM Using a New Syringe in 10 to 15-year Old Adolescents Completed NCT01362322 Phase 4

Search NIH Clinical Center for Diphtheria

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: corynebacterium infections

Genetic Tests for Diphtheria

Anatomical Context for Diphtheria

MalaCards organs/tissues related to Diphtheria:

38
Heart, Kidney, Skin, Testes, Tonsil, Lymph Node, Eye

Publications for Diphtheria

Articles related to Diphtheria:

(show top 50) (show all 912)
# Title Authors Year
1
Cardiac complications in diphtheria and predictors of outcomes. ( 29287886 )
2018
2
A phase I, randomized, controlled, dose-ranging study of investigational acellular pertussis (aP) and reduced tetanus-diphtheria-acellular pertussis (TdaP) booster vaccines in adults. ( 29172945 )
2018
3
Lichen planus following tetanus-diphtheria-acellular pertussis vaccination: A case report and review of the literature. ( 29326823 )
2018
4
Immunization of preterm infants with GSK's hexavalent combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine: A review of safety and immunogenicity. ( 29336924 )
2018
5
Seroepidemiology of diphtheria and pertussis in Chongqing, China: serology-based evidence of Bordetella pertussis infection. ( 29408190 )
2018
6
Treatment of MCPT8<sup>DTR</sup>mice with high- or low-dose diphtheria toxin leads to differential depletion of basophils and granulocyte-macrophage progenitors. ( 29315532 )
2018
7
NMR study of mutations of glycine-52 of the catalytic domain of diphtheria toxin. ( 29216588 )
2018
8
A quality improvement initiative to increase Tdap (tetanus, diphtheria, acellular pertussis) vaccination coverage among direct health care providers at a children's hospital. ( 29217370 )
2018
9
Cutaneous Diphtheria Mimicking Pyoderma Gangrenosum. ( 29282460 )
2018
10
Vascular Endothelial Growth Factor-A165b Restores Normal Glomerular Water Permeability in a Diphtheria-Toxin Mouse Model of Glomerular Injury. ( 29393270 )
2018
11
Development of nanoparticle adjuvants to potentiate the immune response against diphtheria toxoid. ( 29171990 )
2018
12
Optimal route of diphtheria toxin administration to eliminate native nephron progenitor cells inA vivo for kidney regeneration. ( 29408475 )
2018
13
Randomized Controlled Trial of the Safety and Immunogenicity of Revaccination With Tetanus-Diphtheria-Acellular Pertussis Vaccine (Tdap) in Adults 10 Years After a Previous Dose. ( 29438562 )
2018
14
Relationship between patient copayments in Medicare Part D and vaccination claim status for herpes zoster and tetanus-diphtheria-acellular pertussis. ( 29231748 )
2018
15
A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a phase 2/3, randomised controlled non-inferiority trial. ( 29066131 )
2018
16
Nanoporous Microneedle Arrays Effectively Induce Antibody Responses against Diphtheria and Tetanus Toxoid. ( 29375544 )
2017
17
Committee Opinion No. 718 Summary: Update on Immunization and Pregnancy: Tetanus, Diphtheria, and Pertussis Vaccination. ( 28832480 )
2017
18
Cellular Entry of the Diphtheria Toxin Does Not Require the Formation of the Open-Channel State by Its Translocation Domain. ( 28937631 )
2017
19
Post-licensure safety surveillance study of routine use of quadrivalent meningococcal diphtheria toxoid conjugate vaccine. ( 28941623 )
2017
20
Committee Opinion No. 718: Update on Immunization and Pregnancy: Tetanus, Diphtheria, and Pertussis Vaccination. ( 28832489 )
2017
21
Co-administration of BCG and Diphtheria-tetanus-pertussis (DTP) Vaccinations May Reduce Infant Mortality More Than the WHO-schedule of BCG First and Then DTP. A Re-analysis of Demographic Surveillance Data From Rural Bangladesh. ( 28784413 )
2017
22
Tetanus, diphtheria, and acellular pertussis vaccination during pregnancy and reduced risk of infant acute respiratory infections. ( 28916245 )
2017
23
Sex-differential effects of diphtheria-tetanus-pertussis vaccine for the outcome of paediatric admissions? A hospital based observational study from Guinea-Bissau. ( 29107347 )
2017
24
Resurgence of Diphtheria in North Kerala, India, 2016: Laboratory Supported Case-Based Surveillance Outcomes. ( 28913330 )
2017
25
Combined Poly(Lactide-Co-Glycolide) Microspheres Containing Diphtheria Toxoid for a Single-shot Immunization. ( 29238945 )
2017
26
Hib antibody responses in infants following diphtheria, tetanus, acellular pertussis, and conjugated Haemophilus influenzae type b (Hib) combination vaccines with decreasing amounts of tetanus toxoid. ( 29054729 )
2017
27
Receptor-Mediated Enhanced Cellular Delivery of Nanoparticles Using Recombinant Receptor-Binding Domain of Diphtheria Toxin. ( 27959571 )
2017
28
Life-saving diphtheria drug is running out. ( 28082541 )
2017
29
Subcutaneous diphtheria and tetanus vaccines in children with haemophilia: A pilot study and review of the literature. ( 28780770 )
2017
30
Auditory Neuropathy after Damage to Cochlear Spiral Ganglion Neurons in Mice Resulting from Conditional Expression of Diphtheria Toxin Receptors. ( 28743950 )
2017
31
Demand- and supply-side determinants of diphtheria-pertussis-tetanus nonvaccination and dropout in rural India. ( 28081971 )
2017
32
Negative Correlation between Circulating CD4(+)FOXP3(+)CD127(-) Regulatory T Cells and Subsequent Antibody Responses to Infant Measles Vaccine but Not Diphtheria-Tetanus-Pertussis Vaccine Implies a Regulatory Role. ( 28855899 )
2017
33
Human liver chimeric mouse model based on diphtheria toxin-induced liver injury. ( 28785147 )
2017
34
Diphtheria, pertussis, and tetanus: evidence-based management of pediatric patients in the emergency department ( 28749121 )
2017
35
Diphtheria, pertussis, and tetanus: evidence-based management of pediatric patients in the emergency department [digest]. ( 28749625 )
2017
36
Diphtheria vaccine: WHO position paper a89 August 2017. ( 28776357 )
2017
37
Using the 4 Pillarsa8c Practice Transformation Program to increase adolescent human papillomavirus, meningococcal, tetanus-diphtheria-pertussis and influenza vaccination. ( 28947346 )
2017
38
Respiratory diphtheria due to Corynebacterium ulcerans transmitted by a companion dog, Italy 2014. ( 28647898 )
2017
39
A new mouse line for cell ablation by diphtheria toxin subunit A controlled by a Cre-dependent FLEx switch. ( 28875587 )
2017
40
Characterization of serum anti-diphtheria antibody activity following administration of equine anti-toxin for suspected diphtheria. ( 28933665 )
2017
41
Diphtheria vaccine: WHO position paper, August 2017 - Recommendations. ( 28822645 )
2017
42
Augmentation of humoral and cellular immunity in response to Tetanus and Diphtheria toxoids by supercritical carbon dioxide extracts of Hippophae rhamnoides L. leaves. ( 28092864 )
2017
43
Report of diphtheria cases & surveillance among contacts in Dibrugarh, Assam, India. ( 29067988 )
2017
44
A Belgian Serosurveillance/Seroprevalence Study of Diphtheria, Tetanus and Pertussis Using a Luminex xMAP Technology-Based Pentaplex. ( 27171114 )
2016
45
Evaluation of the Immunogenicity of Diphtheria Toxoid Conjugated to Salmonella Typhimurium-Derived OPS in a Mouse Model: A Potential Vaccine Candidate Against Salmonellosis. ( 27660722 )
2016
46
Employers' Views on Influenza and Tetanus-Diphtheria-Pertussis Vaccination in the Workplace. ( 27058495 )
2016
47
Diphtheria outbreak in Lao People's Democratic Republic, 2012-2013. ( 27422343 )
2016
48
The pH-Dependent Trigger in Diphtheria Toxin T Domain Comes with a Safety Latch. ( 27806276 )
2016
49
Process optimization for an industrial-scale production of Diphtheria toxin by Corynebacterium diphtheriae PW8. ( 27640957 )
2016
50
Impact and cost-effectiveness of a second tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine dose to prevent pertussis in the United States. ( 26899377 )
2016

Variations for Diphtheria

Expression for Diphtheria

Search GEO for disease gene expression data for Diphtheria.

Pathways for Diphtheria

Pathways related to Diphtheria according to GeneCards Suite gene sharing:

(show all 33)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.73 DNAJC24 DPH1 DPH2 DPH3 DPH7 EEF2
2
Show member pathways
13.43 CSF2 EGF FURIN HBEGF IL2 IL2RA
3
Show member pathways
13.34 CSF2 EGF IL13 IL2 IL2RA IL2RB
4
Show member pathways
13.3 CSF2 EGF HBEGF IL13 IL2 IL2RA
5
Show member pathways
13.24 CD9 CSF2 EGF IL2 IL2RA IL2RB
6
Show member pathways
13.17 CSF2 EGF HBEGF IL13 IL2 IL2RA
7
Show member pathways
12.97 EEF2 EGF HBEGF IL2 IL2RA IL3
8 12.74 EGF IL13 IL2 IL2RA IL2RB IL3
9
Show member pathways
12.72 FURIN IL13 IL2 IL2RA IL2RB
10 12.47 IL2 IL2RA IL2RB IL3
11 12.35 CSF2 IL2 IL2RA IL2RB
12
Show member pathways
12.08 CSF2 IL2 IL2RA IL2RB IL3
13
Show member pathways
11.9 IL2 IL2RA IL2RB IL3
14
Show member pathways
11.88 IL2 IL2RA IL2RB
15
Show member pathways
11.88 CSF2 EGF IL13 IL2 IL2RA IL2RB
16 11.83 CSF2 IL2 IL2RA IL2RB IL3
17 11.82 CD9 CSF2 IL2RA IL3
18 11.74 EGF IL2 IL2RA IL2RB IL3
19 11.73 IL13 IL2 IL2RA IL2RB
20 11.72 CSF2 IL13 IL2
21
Show member pathways
11.69 CSF2 IL2 IL2RA IL3
22
Show member pathways
11.62 IL2 IL2RA IL2RB
23 11.58 CSF2 EGF IL13
24
Show member pathways
11.56 IL2 IL2RA IL2RB
25
Show member pathways
11.45 CD9 EEF2 FURIN HBEGF TXNRD1
26 11.37 IL13 IL2 IL2RA IL2RB
27 11.26 IL2 IL2RA IL2RB
28
Show member pathways
11.2 DNAJC24 DPH1 DPH2 DPH3 DPH7 EEF2
29
Show member pathways
11.18 CSF2 IL2 IL2RA IL2RB
30 11.17 IL13 IL2 IL2RA
31 11.12 CSF2 IL13 IL2 IL3
32 11.03 CSF2 IL13 IL2 IL3
33 10.94 CSF2 EGF IL13 IL2 IL3

GO Terms for Diphtheria

Cellular components related to Diphtheria according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.65 CD9 FURIN HBEGF IL2RA PLAUR
2 extracellular region GO:0005576 9.61 CSF2 EEF2 EGF FURIN HBEGF IL13
3 external side of plasma membrane GO:0009897 9.46 CD9 IL13 IL2RA IL2RB
4 extracellular space GO:0005615 9.23 CD9 CSF2 EGF FURIN HBEGF IL13

Biological processes related to Diphtheria according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.92 CSF2 EGF HBEGF IL2 IL3
2 immune response GO:0006955 9.88 CSF2 IL13 IL2 IL2RA IL3
3 regulation of receptor activity GO:0010469 9.85 CSF2 HBEGF IL13 IL2 IL3
4 response to ethanol GO:0045471 9.74 EEF2 IL13 IL2
5 peptidyl-tyrosine phosphorylation GO:0018108 9.71 CSF2 EGF HBEGF IL3
6 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.69 EGF HBEGF IL3
7 movement of cell or subcellular component GO:0006928 9.67 CD9 IL13 PLAUR
8 regulation of molecular function GO:0065009 9.63 CSF2 HBEGF IL2 IL2RA IL2RB IL3
9 positive regulation of T cell differentiation GO:0045582 9.56 IL2 IL2RA
10 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.56 CSF2 IL13 IL2 IL3
11 regulation of regulatory T cell differentiation GO:0045589 9.55 IL2 IL2RA
12 negative regulation of ERBB signaling pathway GO:1901185 9.54 EGF HBEGF
13 MAPK cascade GO:0000165 9.5 CSF2 EGF HBEGF IL2 IL2RA IL2RB
14 negative regulation of lymphocyte proliferation GO:0050672 9.43 IL2 IL2RA
15 interleukin-2-mediated signaling pathway GO:0038110 9.37 IL2RA IL2RB
16 regulation of T cell homeostatic proliferation GO:0046013 9.32 IL2 IL2RA
17 peptidyl-diphthamide biosynthetic process from peptidyl-histidine GO:0017183 9.1 DNAJC24 DPH1 DPH2 DPH3 DPH7 EEF2

Molecular functions related to Diphtheria according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.67 CSF2 IL13 IL2 IL3
2 protein tyrosine kinase activity GO:0004713 9.62 CSF2 EGF HBEGF IL3
3 growth factor activity GO:0008083 9.35 CSF2 EGF HBEGF IL2 IL3
4 interleukin-2 receptor activity GO:0004911 9.26 IL2RA IL2RB
5 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.17 CSF2 EGF HBEGF IL2 IL2RA IL2RB
6 interleukin-2 binding GO:0019976 9.16 IL2RA IL2RB

Sources for Diphtheria

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....